Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.
about
NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple MyelomaPhase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaEndocytosis and intracellular trafficking of human natural killer cell receptorsNatural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.Combining immunotherapy and targeted therapies in cancer treatment.Can we change the disease biology of multiple myeloma?Novel immune modulators used in hematology: impact on NK cellsImmunotherapeutic approaches to treat multiple myelomaCancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor ActivitySelective vulnerability of neurons to acute toxicity after proteasome inhibitor treatment: implications for oxidative stress and insolubility of newly synthesized proteins.Transient blocking of NK cell function with small molecule inhibitors for helper dependant adenoviral vector-mediated gene delivery.Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.Bi(o)communications among peripheral blood fractions: a focus on NK and NKT cell biology in rheumatoid arthritis.Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis.The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells.Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
P2860
Q28080823-D5F80007-1FEA-48C6-B1C6-44BC379B2045Q33390073-C6F3F620-94E8-451A-B02B-74F9EECE093BQ33413142-6BD28A71-D060-471F-9FBF-F5C040A1DFC7Q37440077-07209F17-E7B6-4B2C-AB5D-7506AAB9D403Q37779043-9DD903C5-1A40-41C9-BDDC-E2A7ECBFDDCFQ37995939-642E6484-A94D-4B39-B53D-20934C43E515Q38062038-1DB46A72-2491-4000-A2C4-EA34ED67B02CQ38073760-1DF7518F-0AAA-464F-8225-B9CCB0B33A64Q38171067-59C06460-C641-4305-921E-16C41DFFA759Q38203261-864A93EE-FDEC-4795-9B8B-145A95B5BCD6Q38506874-154878EE-B4F0-45D0-94C9-EF3DC3525BE2Q38862771-A10909B3-1BBB-44A7-BA68-0CDD01EEC28BQ39361933-DB4802C8-FF5E-45EA-B990-F38E2C377486Q42738022-F005971D-A69C-47F7-A0CF-ABC82355A5E7Q44814337-3C6F117D-D784-4F53-B091-7033EEFC7452Q48573282-67CF95D9-0867-4E38-9210-F1C8DBBA4928Q52666760-DFEDF987-80EE-4442-AAF2-6AE43E522CECQ57138910-648807D6-3176-4A2C-9655-00BAE60C8020
P2860
Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Proteasome inhibition induces ...... s NKp46-mediated cytotoxicity.
@en
Proteasome inhibition induces ...... s NKp46-mediated cytotoxicity.
@nl
type
label
Proteasome inhibition induces ...... s NKp46-mediated cytotoxicity.
@en
Proteasome inhibition induces ...... s NKp46-mediated cytotoxicity.
@nl
prefLabel
Proteasome inhibition induces ...... s NKp46-mediated cytotoxicity.
@en
Proteasome inhibition induces ...... s NKp46-mediated cytotoxicity.
@nl
P2093
P2860
P50
P356
P1433
P1476
Proteasome inhibition induces ...... s NKp46-mediated cytotoxicity.
@en
P2093
Astrid Ottosson
Chengyun Zheng
Chunyan Ji
Xiangling Wang
Xiaoli Feng
P2860
P304
P356
10.3324/HAEMATOL.13783
P577
2009-02-19T00:00:00Z